Literature DB >> 19196727

HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus.

A M Jacobi1, H Mei, B F Hoyer, I M Mumtaz, K Thiele, A Radbruch, G-R Burmester, F Hiepe, T Dörner.   

Abstract

OBJECTIVES: Monitoring of peripheral B-cell subsets in patients with systemic lupus erythematosus (SLE) revealed an activity-related expansion of CD27(++)CD20(-)CD19(dim) Ig-secreting cells. A similar subset has also been identified 6-8 days after tetanus/diphtheria vaccination in normal individuals and in patients with infectious disease.
METHODS: This subset was analysed further focussing on the HLA-DR surface expression in a cohort of 25 patients with SLE.
RESULTS: This study revealed that 86% (range 59-97%) of CD27(++)CD20(-)CD19(dim) cells express high levels of HLA-DR, are also expanded in the bone marrow, and represent plasmablasts enriched with anti-dsDNA secreting cells. The remaining CD27(++)CD20(-)CD19(dim) cells were HLA-DR(low) and represent mature plasma cells. Importantly, HLA-DR(high) plasmablasts showed a closer correlation with lupus activity and anti-dsDNA levels than the previously identified CD27(++)CD20(-)CD19(dim) cells.
CONCLUSION: HLA-DR(high)CD27(++)CD20(-)CD19(dim) plasmablasts represent a more precise indicator of lupus activity and suggest that there is an overproduction or lack of negative selection of these cells in SLE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19196727     DOI: 10.1136/ard.2008.096495

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  53 in total

Review 1.  Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.

Authors:  Falk Hiepe; Thomas Dörner; Anja E Hauser; Bimba F Hoyer; Henrik Mei; Andreas Radbruch
Journal:  Nat Rev Rheumatol       Date:  2011-02-01       Impact factor: 20.543

2.  Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo.

Authors:  Rebecca A Sweet; Michelle L Ols; Jaime L Cullen; Ashley Viehmann Milam; Hideo Yagita; Mark J Shlomchik
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  [Plasma cells].

Authors:  F Hiepe; T Alexander; R E Voll
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

Review 4.  [Immunological principles of IgG4 related diseases].

Authors:  T Witte
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

5.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

Review 6.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

Review 7.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

8.  Glomerular disease: Personalized immunomonitoring in lupus and lupus nephritis.

Authors:  Hans-Joachim Anders; Matthias Kretzler
Journal:  Nat Rev Nephrol       Date:  2016-05-09       Impact factor: 28.314

9.  Lymphocyte subset clustering analysis in treatment-naive patients with systemic lupus erythematosus.

Authors:  Zhimin Lu; Weiping Li; Yawei Tang; Zhanyun Da; Xia Li
Journal:  Clin Rheumatol       Date:  2020-10-31       Impact factor: 2.980

Review 10.  B cells in autoimmunity.

Authors:  Thomas Dörner; Annett M Jacobi; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.